Maintaining remission in improved dilated cardiomyopathy
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests whether people with dilated cardiomyopathy whose heart function has already recovered to normal can safely stop or reduce one of their heart medications while staying in remission. It aims to find the best way to keep the heart healthy without extra medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with dilated cardiomyopathy (a weakened, enlarged heart).
- Your heart function has improved significantly — it now pumps at over 50% strength, and your heart is not enlarged.
- A blood test for NT-proBNP (a marker of heart strain) is under 250.
- You are in a normal, steady heart rhythm (sinus rhythm) and do not have atrial fibrillation.
- You take daily heart medications: a beta-blocker plus an ACE inhibitor, ARB, or Entresto, and also either an MRA or an SGLT2i (medicines that support the heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether people whose heart failure has improved (with better pumping strength) can safely stop taking some of their heart medications. It is for stable patients who have had significant improvement in their heart function from a low point.
This study tests whether patients whose heart failure has improved can safely reduce some of their medications. If your heart function has recovered significantly and stayed stable, this trial explores whether you can gradually lower doses of heart failure drugs while staying healthy.
This study tests whether patients whose heart function has fully recovered after surgery or a heart procedure can safely reduce or stop their heart failure medications. Researchers will carefully monitor whether gradually lowering these medicines is safe and maintains heart health.
This trial tests whether it is safe to slowly reduce some heart failure medications for people whose heart function has improved to normal. It is for patients who once had a weak heart pump but now have recovered strength and are stable on multiple medicines.
This trial tests whether it is safe and effective to increase heart failure medications (like ACE inhibitors, ARBs, ARNIs, MRAs, or SGLT-2 inhibitors) without frequent kidney monitoring. It is for people with heart failure and reduced ejection fraction who are not yet on full doses of these medicines.
This study looks at whether patients with severe heart failure follow their prescribed medications as recommended by treatment guidelines. The researchers want to understand what helps or prevents patients from taking their medicines correctly, which could improve their heart function and symptoms.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.